Future of the Obesity Market

This chapter examines the evolving landscape of the obesity market with a focus on anticipated clinical trials and the competitive dynamics among major pharmaceutical companies, especially Novo and Lilly. It addresses the potential market volatility linked to trial results and explores the broader implications for smaller biotech firms and new Alzheimer's research.